Manufacturers of permanent static magnet devices claim that they reduce pain in various conditions, including osteoarthritis. 1 Worldwide sales were estimated at $5bn (£2.6bn, €3.8bn) in 1999. 2 Osteoarthritis affects around 760 000 people in the United Kingdom, producing an estimated 3.02 million general practice consultations in 2000. 3 If magnets were effective they would offer a cheap and probably safe treatment option.
Some studies of permanent static magnets have found significant pain reduction 2 4-9 whereas others reported no effect. [10] [11] [12] Major differences exist in the type and strength of magnets used, the conditions treated, and treatment times. There are also methodological concerns about small sample size and difficulties in maintaining blinding. 2 We therefore aimed to conduct an adequately powered trial testing the hypothesis that magnetic bracelets, as used in the consumer market, reduce pain in osteoarthritis of the hip and knee.
Participants and methods
Between December 2001 and December 2003, we recruited 194 participants aged 45-80 years with osteoarthritis of the hip or knee from five rural general practices in Mid Devon (see bmj.com). Osteoarthritis was diagnosed by a consultant (orthopaedic surgeon or rheumatologist) or a general practitioner, and we sought confirmatory radiological evidence for participants who had none recorded in their general practice notes. Participants had to score 8-20 points on the Western Ontario and McMaster Universities osteoarthritis index (WOMAC A) on entry. 13 14 We excluded people with a cardiac pacemaker, current magnetic bracelet, surgery to the index joint (excluding arthroscopy), or haemophilia and women who were pregnant or breast feeding.
Recruitment was by referral from doctors, advertising, or invitation after a search of practice records. Trial nurses arranged radiological confirmation of diagnosis if needed, and they collected data in surgery based clinics at 0, 4, and 12 weeks. Participants were given a full strength bracelet at the end of the trial.
Intervention and randomisation
The participants, trial nurse, and healthcare providers, were blinded to treatment allocation. Treatments consisted of identical looking bracelets containing three different components. The manufacturer's specifications were:
Group A-Standard neodymium magnets set in a steel backing cup, with the open side facing the ventral wrist, creating a fluctuating magnetic pattern across the bracelet (fig 1) . The field strength at the wrist contact surface was 170-200 mTesla.
Group B-Weak magnets with no backing plate. The field was strong enough to seem magnetic on testing (21-30 mTesla), but previous research suggests this is insufficient to be therapeutic. 15 This was intended to provide an undetectable placebo.
Group C-Non-magnetic steel washers.
The National Physical Laboratory tested five bracelets of each type before the study, confirming the manufacturer's specification.
An independent researcher randomised participants in blocks of 15 (five of each bracelet type per block), using random numbers generated in Microsoft Excel. A decode sheet was sealed and locked away. A second researcher checked the procedure. On enrolment, participants were told that they would receive either an active or an inactive bracelet.
Outcome measures
The predefined primary outcome measure was change in WOMAC A score after 12 weeks' follow up. 13 14 Secondary outcomes were a visual analogue scale asking, "How bad was the pain from your arthritis in the last week when it was at its worst?" with verbal and numerical anchors from none (0) to worst imaginable (100) 16 ; WOMAC B and C scores, measuring leg stiffness and functioning 13 14 ; the number of days participants had used analgesics in the past week; and perceived monetary value of the bracelet.
We assessed compliance with wearing the bracelet at 4 and 12 weeks using a visual analogue scale. Blinding was assessed at 12 weeks by asking whether participants thought they had an active bracelet and the reason for such belief.
The estimated effect size was based on a 20% differential reduction in WOMAC A score, which was considered commensurate with effect sizes in studies of analgesics and osteoarthritis. 13 17 A sample size of 52 in each of the groups would have 80% power to detect a difference in one way analysis of variance of change scores, assuming mean changes of 3, 1.5, and 1 and a common standard deviation of 3.4. Assuming 15% dropout, we planned to recruit 64 subjects to each group. 18 We checked the suitability of these numbers for an analysis of variance across the three groups by using a range of estimated small average changes for the weak magnet group.
Analysis
The analysis was specified in advance of the study as follows. Last value carried forward was used to impute missing values for subsequent visits. The blinded statistician conducted analysis of variance on all three groups using SPSS version 11.5, with change in WOMAC A score at 12 weeks as the response. The robustness of the results was checked with analysis of covariance on the WOMAC A score at 12 weeks with baseline WOMAC A as covariate, and checking sensitivity to baseline imbalances. Dunnett's test was then used to compare the means for the dummy and weak magnet group separately with the mean for the standard magnet group. The protocol specified that Magnetic field strength (mTesla) across the surface of a standard magnetic bracelet (20 mm diameter) 
Results

Response rates and sample properties
Of the 391 people assessed for eligibility, 144 did not satisfy the inclusion criteria and 194 (78.5%) of the remaining 247 accepted entry into the trial (see bmj.com). Group baseline characteristics were similar (table 1) . Very few participants were lost to follow up. These were evenly spread across the three groups, and their baseline WOMAC A scores were not markedly different from those of participants with complete data. Reported compliance was high, with most wearing the bracelets for 100% of waking hours.
After the trial, we tested all the returned bracelets using a calibrated Hall effect probe. This showed that the standard magnets had a mean strength of 186 (range 134-197) mTesla (only one was outside the specified range) and the non-magnetic group all had zero strength. Because of a manufacturing error, only 28 of the weak magnets were within the specified range (21-30 mTesla). The mean for these 28 magnets was 26 mTesla; 34 magnets had a strength of 69-196 (mean 128) mTesla, and two were not returned (these were assumed to be in the specified range as they were part of a good batch). Table 2 shows the scores for the three groups at baseline and after 4 and 12 weeks. Analysis of variance between the three groups on the change in WOMAC A from baseline to 12 weeks showed a difference that was just non-significant (F = 2.90, df = 2, 190; P = 0.057). Results from analysis of covariance on the score at 12 weeks (with baseline WOMAC A score entered as a covariate) were significant (F = 3.24, df = 2, 189; P = 0.041).
Analysis of outcomes
The planned comparison (Dunnett's test) showed a significant mean difference in change in WOMAC A score of 1.3 between the standard and dummy magnet groups (95% confidence interval 0.09 to 2.60; P = 0.03), but not between the standard and weak groups (mean difference 0.81, -0.44 to 2.07; P = 0.26). A similar pattern was observed for the change in WOMAC C score. The overall analysis of variance gave significant results (F = 4.45, df = 2, 190; P = 0.013), and Dunnett's test showed a significant mean difference between the standard and dummy groups (4.4, 95% confidence interval 1.0 to 7.9; P = 0.01) but not between the standard and weak groups (3.3, − 0.2 to 6.7; P = 0.07). Analysis of the visual analogue pain score showed a significant mean difference between the standard and dummy groups of 11.4 (95% confidence interval 3.0 to 19.8). Change in WOMAC B scores did not differ between groups (F = 0.73, df = 2, 190; P = 0.48). No important differences in these results emerged when either sex or analgesic use (at 12 weeks) was included as a covariate. Table 3 provides data on participants' beliefs about group allocation and the reasons given for their beliefs. Around a third of participants in the standard and dummy groups were correct in their beliefs about their bracelet, although the reasons differed between groups. In the standard group beliefs were mainly based on noticing the magnetic force-for example, bracelets were often reported to stick to keys in pockets-or on improved symptoms. In the dummy group, few noticed the magnetic force and beliefs were most commonly based on a lack of symptom improvement.
Comparing the outcomes for the different belief groups is not appropriate because belief may follow benefit or lack of it, and any differences would therefore be hard to interpret. 19 However, we have a more direct way of estimating the effect of unblinding, as participants reported whether they had noticed the magnetic strength of their bracelets (table 3) . The overall pattern of results was replicated in the subgroup of 97 participants (41 (63%) in standard group v 56 (88%) 
*Participants who responded don't know were not asked for reasons, but percentages are of total in group.
The limits of medicine in dummy group) who did not report noticing or testing the magnetic strength of their bracelets at week 12.
Results from analysis of covariance estimated the mean difference in WOMAC A between the standard and dummy groups as 1.3 (95% confidence interval 0.003 to 2.62).
To examine the impact of the contamination of the weak magnets on the trial, we analysed data from only the bracelets that met the defined specification (30 weak magnets, 64 dummy magnets, and 64 standard magnets). Analysis of variance showed a significant difference for change in WOMAC A score (F = 3.73, df = 2, 155; P = 0.026). The post-hoc Dunnett's test showed a significant difference between real and dummy magnets (mean difference 1.39, 95% confidence interval 0.11 to 2.68), and a non-significant difference between real and weak magnets, although there was a strong numerical trend (mean difference 1.52, − 0.09 to 3.13, P = 0.067). Table 4 gives data on individual responses to treatments categorised according to predefined criteria for improvement. 17 20 Participants' estimate of the monetary worth of the bracelet did not differ significantly. Adverse reactions were rare, with two participants in each group reporting dizziness, increased pain, or stiffness.
Discussion
We found evidence of a beneficial effect of magnetic wrist bracelets on the pain of osteoarthritis of the hip and knee. Self reported unblinding to treatment group did not substantially affect the results. Although there were problems with the weak magnets, a perspecification analysis suggested (but could not confirm) a specific effect of magnetic bracelets over and above placebo. Other reasons for suspecting a specific effect are that the data on belief show a low level of unblinding in the dummy group and the data on individual responses (table 4) show that more people achieve high levels of improvement in the standard magnet group. The results for two of the secondary outcome measures (WOMAC C and visual analogue pain scores) were consistent with this pattern. No change was seen in WOMAC B score, but this measure has been found to lack sensitivity. 18 The findings are consistent with previous studies on magnetic therapies and pain. Studies that have failed to show an effect on pain 10 12 generally used weaker magnets (19 to 50 mTesla). Studies that have shown an effect used stronger magnets (47 to 180 mTesla), which were comparable with our standard strength magnets. 2 4-8 Together these findings suggest that field strength is important.
Is the effect real?
Our study has not entirely resolved the extent to which the effect of magnetic bracelets is specific or due to placebo. Blinding did not affect the pattern of results, but the validity of the self reporting of blinding status could be questioned. Although the analysis of per-specification bracelets also suggests a specific effect, the result is only a trend and needs confirmation. Therefore, we cannot be certain whether our data show a specific effect of magnets, a placebo effect, or both.
Whatever the mechanism, the benefit from magnetic bracelets seems clinically useful. The mean reduction in WOMAC A scores in the intervention group of 2.9 (27% change from baseline score) and the difference above placebo (1.3 points) is similar to that found in trials of frontline osteoarthritis treatments, including non-steroidal topical creams, 21 oral nonsteroidal drugs (including cyclo-oxygenase 2 inhibitors), 17 and exercise therapy. 22 In a pivotal trial of cyclooxygenase 2 inhibitors 17 in osteoarthritic patients with similar baseline pain (mean WOMAC A score 10.7) and the same follow up period (12 weeks), the treatment effects (change above placebo) were 0.8, 1.5, and 1.9 points for the three doses studied. The difference we found in physical function scores (WOMAC C) also compares well with the above trials. Furthermore, the effects seem additive to those of the participants' usual treatment. The (one off) cost of bracelets (around £30-£50 ($58-$96, €43-€92)), compares well with that of analgesics (paracetamol £20 a year, newer non-steroidal anti-inflammatories £250 a year). 23 Larger investigations should now test the safety of magnets relative to the well known risks of analgesics. 17 23 24 The low refusal rate favours generalisability of our findings. However, the sample selected was predominantly white with a minimum WOMAC A score of 8. Our results may thus not translate to other ethnic populations or people with milder osteoarthritis. Further work is needed to replicate our findings and determine whether the effect extends beyond 12 weeks. The contamination of group B with stronger magnets prevented a more objective estimation of anyplacebo effect. However, our design seems in principle a feasible way to allow for placebo effects in future studies.
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